Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenjie for prevention of oxaliplatin-induced neurotoxicity in advanced colorectal cancer
NCT02024412Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2013
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
A Phase 3 trial of monosialotetrahexosylganglioside in Oxaliplatin-induced peripheral neurotoxicity (OIPN), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
Oxaliplatin-induced peripheral neurotoxicity (OIPN)
Beyond the preview
Go deeper on NCT02024412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02024412.